Tocilizumab-Bavi Suppliers & Bulk Manufacturers

Available Forms: Intravenous infusion

Available Strengths: 80 mg/4ml

Reference Brands: Actemra; Tofidence - biosimilar to Actemra (tocilizumab).

Category: Biosimilars

Tocilizumab-bavi is available in Intravenous infusion and strengths such as 80 mg/4ml. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Tocilizumab-bavi is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Tocilizumab-bavi can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Ofidence, a biosimilar to Actemra (tocilizumab), is regulated in the EU and US, supported by dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality according to GMP standards. In the US, FDA approval involves extensive comparability data, clinical validation, and safety assessments. In the EU, CE marking confirms conformity with MDR standards. These biosimilars undergo validation, stability testing, and audits, with comprehensive documentation including biosimilarity, clinical data, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to affordable, high-quality biosimilar therapies for inflammatory and autoimmune diseases globally.